ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents

Katie Larson Ode¹, Manfred Ballman², Alberto Battezzati³, Amanda Brennan⁴, Christine L Chan⁵, Shihab Hameed^{6

7

8}, Heba M Ismail⁹, Andrea Kelly^{10

11}, Antoinette M Moran¹², Remi Rabasa-Lhoret¹³, Nichole A Saxby¹⁴, Maria E Craig^{15

16}

Affiliations

¹ University of Iowa Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA.
² University Medicine Rostock, Rostock, Mecklenburg-Vorpommern, Germany.
³ International Center for the Assessment of Nutritional Status, DeFENS, University of Milan, Milan, Italy.
⁴ Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
⁵ University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, USA.
⁶ Sydney Children's Hospital, Randwick and Royal North Shore Hospital, St. Leonards, New South Wales, Australia.
⁷ School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
⁸ Pediatric Endocrinology, University of Sydney, Camperdown, Australia.
⁹ Department of Pediatrics, Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁰ Department of Pediatrics, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹¹ Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
¹² Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
¹³ Division of Experiemental Medicine, Montreal Clinical Research institute, Montreal, Canada.
¹⁴ Women's and Children's Services, Royal Hobart Hospital, Hobart, Tasmania, Australia.
¹⁵ The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia.
¹⁶ School of Women's and Children's Health, University of NSW, Sydney, New South Wales, Australia.

PMID: 36537525
PMCID: PMC10108242
DOI: 10.1111/pedi.13453

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents

Katie Larson Ode et al. Pediatr Diabetes. 2022 Dec.

. 2022 Dec;23(8):1212-1228.

doi: 10.1111/pedi.13453.

Authors

Affiliations

¹ University of Iowa Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA.
² University Medicine Rostock, Rostock, Mecklenburg-Vorpommern, Germany.
³ International Center for the Assessment of Nutritional Status, DeFENS, University of Milan, Milan, Italy.
⁴ Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
⁵ University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, Colorado, USA.
⁶ Sydney Children's Hospital, Randwick and Royal North Shore Hospital, St. Leonards, New South Wales, Australia.
⁷ School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
⁸ Pediatric Endocrinology, University of Sydney, Camperdown, Australia.
⁹ Department of Pediatrics, Pediatric Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁰ Department of Pediatrics, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹¹ Division of Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
¹² Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
¹³ Division of Experiemental Medicine, Montreal Clinical Research institute, Montreal, Canada.
¹⁴ Women's and Children's Services, Royal Hobart Hospital, Hobart, Tasmania, Australia.
¹⁵ The Children's Hospital at Westmead, University of Sydney, Sydney, New South Wales, Australia.
¹⁶ School of Women's and Children's Health, University of NSW, Sydney, New South Wales, Australia.

PMID: 36537525
PMCID: PMC10108242
DOI: 10.1111/pedi.13453

No abstract available

Keywords: CFTR modulator; HEMT therapy; adolescents; children; cystic fibrosis related diabetes.

PubMed Disclaimer

References

1. Ibarra‐Gonzalez I, Campos‐Garcia FJ, Herrera‐Perez LDA, et al. Newborn cystic fibrosis screening in southeastern Mexico: birth prevalence and novel CFTR gene variants. J Med Screen. 2018;25(3):119‐125. doi:10.1177/0969141317722808 - DOI - PubMed
1. Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33(2):311‐316. doi:10.2337/dc09-1215 - DOI - PMC - PubMed
1. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891‐895. doi:10.1164/ajrccm.162.3.9904075 - DOI - PubMed
1. Lewis C, Blackman SM, Nelson A, et al. Diabetes‐related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191(2):194‐200. doi:10.1164/rccm.201403-0576OC - DOI - PMC - PubMed
1. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis‐related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697‐2708. doi:10.2337/dc10-1768 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents

Affiliations

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents

Authors

Affiliations

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical